Search

Your search keyword '"Oliva, Angelo"' showing total 17 results
Start Over Author "Oliva, Angelo" Search Limiters Available in Library Collection
17 results on '"Oliva, Angelo"'

5. TCT-764 Left Main Percutaneous or Surgical Revascularization and Subsequent Risk of Acute Kidney Injury: The LUCKY Registry

Author

Novelli, Laura, primary, Sanchez, Jorge Sanz, additional, Iaccarino, Alessandra, additional, Oliva, Angelo, additional, Gasparini, Gabriele, additional, Stefanini, Giulio, additional, Regazzoli, Damiano, additional, Mangieri, Antonio, additional, Cantisani, Gaia, additional, Ferrante, Giuseppe, additional, Calderon, Andrea Teira, additional, Romero, Jose Sorolla, additional, Torracca, Lucia, additional, Reimers, Bernhard, additional, Colombo, Antonio, additional, and Chiarito, Mauro, additional

Published
2023
Full Text
View/download PDF

6. A Keynesian perspective on the health economics of kidney transplantation would strengthen the value of the whole organ donation and transplantation service

Author

Leonardis, Francesca, primary, Gitto, Lara, additional, Favi, Evaldo, additional, Oliva, Angelo, additional, Angelico, Roberta, additional, Mitterhofer, Annapaola, additional, Cacciola, Irene, additional, Santoro, Domenico, additional, Manzia, Tommaso Maria, additional, Tisone, Giuseppe, additional, and Cacciola, Roberto, additional

Published
2023
Full Text
View/download PDF

8. 898 ROLE OF 3D ECHOCARDIOGRAPHY IN AORTIC VALVE ABNORMALITIES: TWO CASES REPORT

Author

Monaco, Maria Lo, primary, Stankowski, Kamil, additional, Oliva, Angelo, additional, Figliozzi, Stefano, additional, Fazzari, Fabio, additional, Mantovani, Riccardo, additional, Curzi, Mirko, additional, Cannata, Francesco, additional, Marconi, Manuel, additional, Fumero, Andrea Davide, additional, Stefanini, Giulio Giuseppe, additional, Torracca, Lucia, additional, Bragato, Renato Maria, additional, Volpe, Massimo, additional, and Condorelli, Gianluigi, additional

Published
2022
Full Text
View/download PDF

10. 759 LEFT MAIN PERCUTANEOUS OR SURGICAL REVASCULARIZATION AND SUBSEQUENT RISK OF ACUTE KIDNEY INJURY: INSIGHTS FROM THE LUCKY REGISTRY

Author

Terzi, Riccardo, primary, Chiarito, Mauro, additional, Oliva, Angelo, additional, Iaccarino, Alessandra, additional, Novelli, Laura, additional, Carnabuci, Anna Giuli, additional, Regazzoli, Damiano, additional, Mangieri, Antonio, additional, Sticchi, Alessandro, additional, Ferrante, Giuseppe, additional, Sturla, Matteo, additional, Gasparini, Gabriele, additional, Pagnotta, Paolo, additional, Colombo, Antonio, additional, Condorelli, Gianluigi, additional, Barbone, Alessandro, additional, Torracca, Lucia, additional, Reimers, Bernhard, additional, Mehran, Roxana, additional, and Stefanini, Giulio G, additional

Published
2022
Full Text
View/download PDF

11. 760 IMPACT OF COMORBIDITIES AND PATIENTS PREFERENCE ON THE CHOICE BETWEEN PERCUTANEOUS OR SURGICAL REVASCULARIZATION FOR LEFT MAIN CORONARY ARTERY DISEASE

Author

Chiarito, Mauro, primary, Oliva, Angelo, additional, Novelli, Laura, additional, Terzi, Riccardo, additional, Sturla, Matteo, additional, Lacevic, Emir, additional, Carnabuci, Anna Giulia, additional, Regazzoli, Damiano, additional, Mangieri, Antonio, additional, Sticchi, Alessandro, additional, Ferrante, Giuseppe, additional, Gasparini, Gabriele, additional, Pagnotta, Paolo, additional, Colombo, Antonio, additional, Mehran, Roxana, additional, Torracca, Lucia, additional, Condorelli, Gianluigi, additional, Reimers, Bernhard, additional, and Stefanini, Giulio G, additional

Published
2022
Full Text
View/download PDF

12. 481 VITAMIN K ANTAGONISTS, DIRECT ORAL ANTICOAGULANTS, OR LEFT ATRIAL APPENDAGE CLOSURE FOR PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Author

Oliva, Angelo, primary, Maria Ioppolo, Anna, additional, Chiarito, Mauro, additional, Cremonesi, Alberto, additional, Azzano, Alessia, additional, Micciché, Eligio, additional, Mangiameli, Andrea, additional, Ariano, Francesco, additional, Ferrante, Giuseppe, additional, Reimers, Bernhard, additional, Garot, Philippe, additional, Amabile, Nicolas, additional, Condorelli, Gianluigi, additional, Stefanini, Giulio, additional, and Cao, Davide, additional

Published
2022
Full Text
View/download PDF

13. TCT-539 Left Main Percutaneous or Surgical Revascularization and Subsequent Risk of Acute Kidney Injury: Insights From the LUCKY Registry

Author

Chiarito, Mauro, primary, Oliva, Angelo, additional, Iaccarino, Alessandra, additional, Novelli, Laura, additional, Terzi, Riccardo, additional, Carnabuci, Anna Giulia, additional, Regazzoli, Damiano, additional, Mangieri, Antonio, additional, Sticchi, Alessandro, additional, Ferrante, Giuseppe, additional, Gasparini, Gabriele, additional, Pagnotta, Paolo, additional, Colombo, Antonio, additional, Mehran, Roxana, additional, Torracca, Lucia, additional, Reimers, Bernhard, additional, and Stefanini, Giulio, additional

Published
2022
Full Text
View/download PDF

14. 112 Safety and biochemical efficacy of sodium–glucose cotransporter 2 inhibitors based on cardiovascular risk profile and volume status in a real-world diabetic population

Author

Gitto, Mauro, primary, Kotinas, Alexios, additional, Terzi, Riccardo, additional, Oliva, Angelo, additional, Zagoreo, Jorgele, additional, Reimers, Bernhard, additional, Stefanini, Giulio G, additional, Mirani, Marco, additional, Favacchio, Giuseppe, additional, Condorelli, Gianluigi, additional, and Panico, Cristina, additional

Published
2021
Full Text
View/download PDF

16. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease. Two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC) and European Association of Preventive Cardiology (EAPC)

Author

Eliano Pio Navarese, Antonio Landi, Angelo Oliva, Raffaele Piccolo, Victor Aboyans, Dominick Angiolillo, Dan Atar, Davide Capodanno, Keith A A Fox, Sigrun Halvorsen, Stefan James, Peter Jüni, Vijay Kunadian, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Josef Niebauer, Susanna Price, Robert F Storey, Heinz Völler, Pascal Vranckx, Stephan Windecker, Marco Valgimigli, Oliva, Angelo/0000-0003-0561-7563, Juni, Peter/0000-0002-5985-0670, Storey, Robert/0000-0002-6677-6229, Leonardi, Sergio/0000-0002-4800-6132, Navarese, Eliano Pio, Landi, Antonio, Oliva, Angelo, Piccolo, Raffaele, Aboyans, Victor, Angiolillo, Dominick, Atar, Dan, Capodanno, Davide, Fox, Keith A. A., Halvorsen, Sigrun, James, Stefan, Juni, Peter, Kunadian, Vijay, Leonardi, Sergio, Mehran, Roxana, Montalescot, Gilles, Niebauer, Josef, Price, Susanna, Storey, Robert F., Voller, Heinz, VRANCKX, Pascal, Windecker, Stephan, and Valgimigli, Marco

Subjects
Antithrombotics, Pharmacology (medical), Cardiology and Cardiovascular Medicine, Network meta-analysis, 610 Medicine & health, Coronary artery disease
Abstract

Aims To appraise all available antithrombotic treatments within or after 12 months following coronary revascularization and/or acute coronary syndrome in two network meta-analyses. Methods and results Forty-three (N = 189 261 patients) trials within 12 months and 19 (N = 139 086 patients) trials beyond 12 months were included for efficacy/safety endpoints appraisal. Within 12 months, ticagrelor 90 mg bis in die (b.i.d.) [hazard ratio (HR), 0.66; 95% confidence interval (CI), 0.49–0.88], aspirin and ticagrelor 90 mg (HR, 0.85; 95% CI, 0.76–0.95), or aspirin, clopidogrel and rivaroxaban 2.5 mg b.i.d. (HR, 0.66; 95% CI, 0.51–0.86) were the only treatments associated with lower cardiovascular mortality, compared with aspirin and clopidogrel, without or with greater bleeding risk for the first and the other treatment options, respectively. Beyond 12 months, no strategy lowered mortality; compared with aspirin; the greatest reductions of myocardial infarction (MI) were found with aspirin and clopidogrel (HR, 0.68; 95% CI, 0.55–0.85) or P2Y12 inhibitor monotherapy (HR, 0.76; 95% CI: 0.61–0.95), especially ticagrelor 90 mg (HR, 0.54; 95% CI, 0.32–0.92), and of stroke with VKA (HR, 0.56; 95% CI, 0.44–0.76) or aspirin and rivaroxaban 2.5 mg (HR, 0.58; 95% CI, 0.44–0.76). All treatments increased bleeding except P2Y12 monotherapy, compared with aspirin. Conclusion Within 12 months, ticagrelor 90 mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel. Beyond 12 months, P2Y12 monotherapy, especially ticagrelor 90 mg, was associated with lower MI without bleeding trade-off; aspirin and rivaroxaban 2.5 mg most effectively reduced stroke, with a more acceptable bleeding risk than VKA, compared with aspirin. Registration URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifiers: CRD42021243985 and CRD42021252398.

Published
2023
Full Text
View/download PDF

17. Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis

Author

Giovanni Esposito, Peter Jüni, Raffaele Piccolo, Marco Valgimigli, Stephan Windecker, Anna Franzone, Angelo Oliva, Marisa Avvedimento, Piccolo, Raffaele, Oliva, Angelo, Avvedimento, Marisa, Franzone, Anna, Windecker, Stephan, Valgimigli, Marco, Esposito, Giovanni, and Jüni, Peter

Subjects
education.field_of_study, Acute coronary syndrome, medicine.medical_specialty, business.industry, medicine.medical_treatment, Hazard ratio, Population, Percutaneous coronary intervention, medicine.disease, Coronary artery disease, Meta-analysis, Internal medicine, Risk of mortality, medicine, Cardiology, Myocardial infarction, education, Cardiology and Cardiovascular Medicine, business
Abstract

Background Bleeding is the principal safety concern of antithrombotic therapy and occurs frequently among patients with coronary artery disease (CAD). Aims We aim to evaluate the prognostic impact of bleeding on mortality compared with that of myocardial infarction (MI) in patients with CAD. Methods We searched Medline and Embase for studies that included patients with CAD and that reported both, the association between the occurrence of bleeding and mortality, and between the occurrence of MI and mortality within the same population. Adjusted hazard ratios (HRs) for mortality associated with bleeding and MI were extracted and ratio of hazard ratios (rHRs) were pooled by using inverse variance weighted random effects meta-analyses. Early events included periprocedural or within 30-day events after revascularization or acute coronary syndrome (ACS). Late events included spontaneous or beyond 30-day events after revascularization or ACS. Results 141,059 patients were included across 16 studies and 128,660 (91%) underwent percutaneous coronary intervention. Major bleeding increased the risk of mortality to the same extent of MI (ratioHR bleedingvsMI 1.10, 95% CI, 0.71–1.71, P=0.668). Early bleeding was associated with a higher risk of mortality than early MI (ratioHR bleedingvsMI 1.46, 95% CI, 1.13–1.89, P=0.004), although this finding was not present when only randomized trials were included. Late bleeding was prognostically comparable to late MI (ratioHR bleedingvsMI 1.14, 95% CI, 0.87–1.49, P=0.358). Conclusions Compared with MI, major and late bleeding is associated with a similar increase in mortality, whereas early bleeding might have a stronger association with mortality. Impact on daily practice. Major and late bleeding should be considered prognostically equivalent to MI, given the similar association with mortality. Early bleeding has even a stronger association with mortality than early MI, emphasizing the importance of bleeding avoidance strategies among patients undergoing PCI. Funding Acknowledgement Type of funding sources: None. Visual AbstractBleeding vs MI risk of mortality

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results